Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: ohno y. Target Oncol. 2024 May;19(3):401-410. doi: 10.1007/s11523-024-01047-y. Epub 2024 Mar 28. Target Oncol. 2024. PMID: 38546942
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases.
Nishio K, Higashio T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Tsuchida S, Matsuda T, Tsujino T, Nishimura K, Tokushige S, Nakamori K, Uchimoto T, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H. Nishio K, et al. Among authors: ohno y. Oncology. 2024;102(6):457-464. doi: 10.1159/000534554. Epub 2023 Oct 13. Oncology. 2024. PMID: 37839399
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T, Matsuda T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Tsuchida S, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: ohno y. Target Oncol. 2024 Jul;19(4):635-644. doi: 10.1007/s11523-024-01068-7. Epub 2024 May 28. Target Oncol. 2024. PMID: 38807017
Handgrip strength as a marker of frailty in patients with transcatheter edge-to-edge repair: Insights from the OCEAN-mitral registry.
Saji M, Nanasato M, Takamisawa I, Higuchi R, Izumi Y, Iwakura T, Isobe M, Ikeda T, Yamamoto M, Kubo S, Asami M, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Yamaguchi J, Naganuma T, Bota H, Ohno Y, Hachinohe D, Yamawaki M, Ueno H, Mizutani K, Otsuka T, Hayashida K; OCEAN-Mitral investigators. Saji M, et al. Among authors: ohno y. Int J Cardiol. 2024 Nov 19;420:132743. doi: 10.1016/j.ijcard.2024.132743. Online ahead of print. Int J Cardiol. 2024. PMID: 39566587
Predictors and clinical impact of worsening left ventricular ejection fraction after mitral transcatheter edge-to-edge repair.
Ono S, Kubo S, Maruo T, Nishiura N, Mushiake K, Osakada K, Kadota K, Yamamoto M, Saji M, Asami M, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Yamaguchi J, Nakajima Y, Naganuma T, Bota H, Ohno Y, Yamawaki M, Ueno H, Mizutani K, Otsuka T, Hayashida K, Investigators OM. Ono S, et al. Among authors: ohno y. EuroIntervention. 2024 Nov 18;20(22):1430-1441. doi: 10.4244/EIJ-D-23-01092. EuroIntervention. 2024. PMID: 39552478 Free article.
2,696 results